The Integrated Forecasting and Analysis Tool   Login Now

Millennium Pharmaceuticals

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for Millennium Pharmaceuticals are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on Millennium Pharmaceuticals, or on any other Company covered by EvaluatePharma® Contact Us today.

CONSENSUS FORECASTS ($US mln) -  Sales Forecasts available to EvaluatePharma Subscribers

Annual Sales WW - Sales Growth per Year (%)   Rank Product Generic Name Pharmacological Class 2006 2007 2007 Millennium Pharmaceuticals 1 Velcade bortezomib Proteasome inhibitor 220 265   20%       Note: Shaded Cells

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

Millennium Pharmaceuticals   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 8,172 8,172        PE Ratio (diluted) - Normalised (x) (88.3) (2,193.1)        Valuing the Enterprise        Enterprise Value 8,172 8,172        Free Cash Flow (Pre-Dividends) (62) (21)        FCF Yield (%) (0.8%) (0.3%)    Forecast Financials   Income Statement      Total Revenues 558 487      Cost of Goods Sold (141) (45)      S,G & A (181) (157)      R&D (342) (311)      Other Income/ Expense - Net 0 3      EBIT - Normalised (106) (23)      Net Interest & Financial Items 19 20      Pre-tax Profits - Normalised (87) (4)      Exceptionals (111) (40)      Income Before Taxes (198) (44)      Tax 0 0      Tax Rate (%) 0.0% 0.0%      Net Income - Reported (198) (44)      Net Income - Normalised (87) (4)     Per Share Data      EPS - Diluted (0.64) (0.14)      EPS - Basic (0.64) (0.14)      EPS - Normalised (diluted) (0.28) (0.01)      EPS - Normalised (basic) (0.28) (0.01)      Avg. Shares Outstanding - Diluted 308.3 313.7      Avg. Shares Outstanding - Basic 308.3 313.7      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

Millennium Expands IBD Franchise with Addition of New Development Candidate   (Millennium Pharmaceuticals)   17-Mar-2008 Publication of Clinical Results Underscores VELCADE(R) (Bortezomib) For Injection Based Therapy As a Standard of Care In Newly Diagnosed Multiple Myeloma Patients   (Millennium Pharmaceuticals)   13-Mar-2008 Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkin's Lymphoma   (Millennium Pharmaceuticals)   20-Feb-2008 Millennium must work hard for Velcade advantage   (Millennium Pharmaceuticals)   12-Feb-2008 FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma   (Millennium Pharmaceuticals)   30-Jan-2008 Millennium Submits sNDA for VELCADE(R) (Bortezomib) for Injection for the Treatment of Front-Line Multiple Myeloma   (Millennium Pharmaceuticals)   21-Dec-2007 Submission of Marketing Authorisation Application for VELCADE® (bortezomib) in Europe   (Johnson & Johnson)   21-Dec-2007 VELCADE(R) (Bortezomib) for Injection Based Therapy Produced Significant Complete Remission Rates Pre- and Post-Transplantation in IFM Phase III Front-Line Multiple Myeloma Trial   (Millennium Pharmaceuticals)   10-Dec-2007 Highest Reported Complete Remission Rate of 35 Percent Achieved in a Phase III Front-Line Multiple Myeloma Trial With Velcade(R) (Bortezomib) for Injection Based Therapy   (Millennium Pharmaceuticals)   09-Dec-2007 Phase III Trial of VELCADE(R) (Bortezomib) for Injection Showed Dramatic Fourfold Increase in Complete Remission Rates When Combined With the Most Commonly Used U.S. Regimen in Front-Line Multiple Myeloma   (Millennium Pharmaceuticals)   09-Dec-2007 New Data to Support VELCADE(R) (Bortezomib) For Injection Based Therapies as Setting New Standards in The Care of Newly Diagnosed Patients With Multiple Myeloma   (Millennium Pharmaceuticals)   26-Nov-2007 Millennium Announces MLN1202 Significantly Reduced Marker of Systemic Inflammation and Identifies Genomic Biomarker For Responders   (Millennium Pharmaceuticals)   06-Nov-2007 FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma   (Millennium Pharmaceuticals)   15-Oct-2007 Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma   (Millennium Pharmaceuticals)   15-Aug-2007 Millennium Initiates Phase III Trial to Determine the Optimal VELCADE(R) (Bortezomib) for Injection Based Therapy in Newly Diagnosed Multiple Myeloma Patients   (Millennium Pharmaceuticals)   16-Jul-2007 VELCADE(R) (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival   (Millennium Pharmaceuticals)   02-Jul-2007 VELCADE(R) (Bortezomib) for Injection Addressed Disease-Related Complications Associated with Multiple Myeloma   (Millennium Pharmaceuticals)   28-Jun-2007 VELCADE(R) (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma   (Millennium Pharmaceuticals)   28-Jun-2007 VELCADE(R) (Bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients   (Millennium Pharmaceuticals)   28-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name Millennium Pharmaceuticals 1228 MAb -   ACE2/SARS Research Project -   Activase alteplase   ADP receptor antagonist -   agCD3 -   Antibacterial agent -   Campath/MabCampath alemtuzumab   Cardiovascular Research Project -   CCR3 Antagonist -   CCR5 Antagonist -   CD28 homologue MAb Project -   Chemokine receptor MAb Project -   Cromafiban cromafiban   FATP4 -   ICAST -   Inflammatory Disorder Research Project -   Integrilin eptifibatide   Integrin signal transduction -   LDP-392 -   MLN2201 -   MLN2222 -   MLN2704 -   MLN273 -   MLN-3897 -   MLN4760 -   MLN519 -   MLN576 -   MLN591RL -   MLN608 -   MLN612 -   MLN944 -   MLN977 -   Myocardial signal transduction -   Platelet-derived growth factor antagonist -   STG-A-IR9 -   STG-A-IT -   STG-A-MD -   STG-A-MD-4Ag -   STG-A-MD-4Ant -   STG-A-MDCHR -   STG-A-MDreh -   Thrombin receptor inhibitor -   TNKase tenecteplase   Velcade bortezomib

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 14:12:28 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd